X0202 SCHEDULE 13D/A 0001273782 XXXXXXXX LIVE 3 Common Stock, par value $0.001 per share 10/28/2026 true 0001680378 81720R604 SenesTech, Inc.

13430 NORTH DYSART ROAD SUITE 105 SURPRISE AZ 85379

Glenbrook Capital Management 650-441-9525 2207, Suite B Bellanca St. Minden NV 89423 Ele Klein & Danny Goldstein 212-756-2446 McDermott Will & Schulte LLP 919 Third Avenue New York NY 10022 0001273782 N GLENBROOK CAPITAL MANAGEMENT AF N NV 0.00 2196973.00 0.00 2196973.00 2196973.00 N 40.51 CO Based on 5,423,542 shares of Common Stock outstanding as of August 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 6, 2026. Common Stock, par value $0.001 per share SenesTech, Inc. 13430 NORTH DYSART ROAD SUITE 105 SURPRISE AZ 85379 This Amendment No. 3 ("Amendment No. 3") amends the statement on Schedule 13D filed with the SEC on July 23, 2026, as amended by Amendment No. 1 filed with the SEC on October 19, 2026 and Amendment No. 2 filed with the SEC on October 22, 2026 (as amended, the "Schedule 13D") with respect to the Common Stock of the Issuer. This Amendment No. 3 amends Item 3, Item 4, and 5(a)-(c), as set forth below. Capitalized terms used herein and not otherwise defined in this Amendment No. 3 have the meanings set forth in the Schedule 13D. Item 3 is hereby amended and restated as follows: Funds for the purchase of the securities reported herein were derived from the general working capital of the Glenbrook Funds and Accounts. A total of approximately $4.43 million (excluding brokerage commissions) was paid to acquire shares of Common Stock during the period in which the Reporting Person has been subject to reporting obligations under Section 13(d) or 13(g) of the Act with respect to the Common Stock. Such amount does not include the price of shares of Common Stock acquired and/or sold by the Reporting Person prior to such period. Item 4 is hereby amended and supplemented by adding the following: In April 2026, the Reporting Person commissioned, at its expense, a strategic study of the rodent control market by Sandstrom Partners, Inc. ("Sandstrom"), the results of which were presented to the Board. On October 28, 2026, the Issuer announced that it had engaged Sandstrom as a strategic advisor on marketing and branding. The Reporting Person holds a minority ownership interest in Sandstrom. Item 5(a) is hereby amended and restated as follows: See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of shares of Common Stock beneficially owned by the Reporting Person. The aggregate percentage of shares of Common Stock reported to be beneficially owned by the Reporting Person is based upon 5,423,542 shares of Common Stock outstanding as of August 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 6, 2026. Item 5(b) is hereby amended and restated as follows: See rows (7) through (10) of the cover page to this Schedule 13D for the number of shares of Common Stock as to which the Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. Item 5(c) is hereby amended and restated as follows: All transactions in the shares of Common Stock effected by the Reporting Person since the filing of Amendment No. 2, which were all in the open market, are set forth in Schedule A hereto, and are incorporated herein by reference. EX 99.1 TRANSACTIONS IN SECURITIES OF THE ISSUER GLENBROOK CAPITAL MANAGEMENT /s/ Robert W. Lishman 10/30/2026